Aquestive Therapeutics (NASDAQ:AQST) Earns Buy Rating from HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 173.97% from the company’s current price.

Other analysts also recently issued reports about the company. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price on the stock. JMP Securities reissued a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Finally, Leerink Partners lifted their target price on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $11.00.

Aquestive Therapeutics Stock Up 0.3 %

Shares of NASDAQ:AQST opened at $3.65 on Friday. Aquestive Therapeutics has a 52 week low of $1.84 and a 52 week high of $6.23. The company has a market cap of $332.80 million, a P/E ratio of -8.11 and a beta of 2.62. The company has a 50-day moving average price of $4.71 and a 200 day moving average price of $4.08.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to the consensus estimate of $12.69 million. During the same quarter in the prior year, the firm earned ($0.03) EPS. Analysts expect that Aquestive Therapeutics will post -0.47 EPS for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC boosted its position in shares of Aquestive Therapeutics by 285.4% in the third quarter. Barclays PLC now owns 99,312 shares of the company’s stock worth $495,000 after acquiring an additional 73,542 shares during the last quarter. Geode Capital Management LLC raised its holdings in Aquestive Therapeutics by 5.7% in the third quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock valued at $8,306,000 after buying an additional 90,543 shares during the period. Wellington Management Group LLP purchased a new stake in Aquestive Therapeutics during the third quarter worth approximately $922,000. State Street Corp increased its position in shares of Aquestive Therapeutics by 52.1% in the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after acquiring an additional 512,682 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at $995,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.